Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
LDL-cholesterol (LDL-C) uptake by Ldlr is regulated at the transcriptional level by the cleavage-dependent activation of membrane-associated sterol response element-binding protein (SREBP-2). Activated SREBP-2 translocates to the nucleus, where it binds to an
LDLR
promoter sterol response element (SRE), increasing
LDLR
gene expression and LDL-C uptake. SREBP-2 cleavage and translocation steps are well established. Several SREBP-2 phosphorylation sites have been mapped and functionally characterized. The phosphatases dephosphorylating these sites remain elusive. The phosphatase(s) regulating SREBP-2 represents a novel pharmacological target for treating hypercholesterolemia. Here we show that protein phosphatase 2A (
PP2A
) promotes SREBP-2
LDLR
promoter binding in response to cholesterol depletion. No binding to an
LDLR
SRE was observed in the presence of the HMG-CoA reductase inhibitor, lovastatin, when
PP2A
activity was inhibited by okadaic acid or depleted by siRNA methods. SREBP-2 cleavage and nuclear translocation were not affected by loss of
PP2A
.
PP2A
activity was required for SREBP-2 DNA binding. In response to cholesterol depletion,
PP2A
directly interacted with SREBP-2 and altered its phosphorylation state, causing an increase in SREBP-2 binding to an
LDLR
SRE site. Increased binding resulted in induced
LDLR
gene expression and increased LDL uptake. We conclude that
PP2A
activity regulates cholesterol homeostasis and LDL-C uptake.
...
PMID:Protein phosphatase 2A (PP2A) regulates low density lipoprotein uptake through regulating sterol response element-binding protein-2 (SREBP-2) DNA binding. 2477 Apr 87